Author:
Topletz-Erickson Ariel R.,Mayor JoAl G.,Liu Hsu-Tai,Abdulrasool Layth I.,Endres Christopher J.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. E14 Implementation Working Group. ICH E14 guideline: the clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs questions & answers (R3). Available at: https://database.ich.org/sites/default/files/E14_Q%26As_R3_Q%26As.pdf. Accessed 23 Mar 2023.
2. Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz H, McCall S, Penault-Llorca F, et al. Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer. Ann Oncol. 2018;29(5):1108–19. https://doi.org/10.1093/annonc/mdy100.
3. Kulukian A, Lee P, Taylor J, Rosler R, de Vries P, Watson D, et al. Preclinical activity of HER2-selective tyrosine kinase inhibitor tucatinib as a single agent or in combination with trastuzumab or docetaxel in solid tumor models. Mol Cancer Ther. 2020;19(4):976–87. https://doi.org/10.1158/1535-7163.Mct-19-0873.
4. Seagen Inc. Tukysa (tucatinib): European summary of product characteristics. Available at: https://www.ema.europa.eu/en/documents/product-information/tukysa-epar-product-information_en.pdf. Accessed 12 Jan 2023.
5. US FDA. TUKYSA US Prescribing information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/213411s004lbl.pdf. Accessed 6 Mar 2023.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献